Checkmate Pharmaceuticals (CMPI)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	39.50 mm	39.50 mm	39.50 mm	39.50 mm	39.50 mm	39.50 mm
Cash burn (monthly)	3.73 mm	(no burn)	5.30 mm	5.26 mm	3.56 mm	4.17 mm
Cash used (since last report)	122.36 mm	n/a	173.60 mm	172.59 mm	116.60 mm	136.81 mm
Cash remaining	-82.86 mm	n/a	-134.10 mm	-133.09 mm	-77.10 mm	-97.31 mm
Runway (months of cash)	-22.2	n/a	-25.3	-25.3	-21.7	-23.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q1 2022

CMPI institutional ownership history Ownership history

61.2% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	24	9	+166.7%
Opened positions	16	0	NEW
Closed positions	1	22	-95.5%
Increased positions	1	1	–
Reduced positions	4	2	+100.0%

13F shares	Current	Prev Q	Change
Total value	43.06 mm	6.41 mm	+571.7%
Total shares	13.50 mm	4.40 mm	+206.5%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Sofinnova Investments	3.61 mm	$11.51 mm	NEW
Novo Holdings A/S	2.16 mm	$6.90 mm	-0.4%
Medicxi Ventures Management	1.50 mm	$4.79 mm	0.0%
Omega Fund Management	1.34 mm	$4.26 mm	NEW
Decheng Capital Management III	1.33 mm	$4.25 mm	NEW
Clough Capital Partners L P	1.14 mm	$3.63 mm	NEW
FMR	966.23 k	$3.08 mm	NEW
Vanguard	556.42 k	$1.78 mm	NEW
Sectoral Asset Management	541.77 k	$1.73 mm	-0.0%
Bridgeway Capital Management	106.50 k	$340.00 k	NEW

Largest transactions	Shares	Bought/sold	Change
Sofinnova Investments	3.61 mm	+3.61 mm	NEW
Omega Fund Management	1.34 mm	+1.34 mm	NEW
Decheng Capital Management III	1.33 mm	+1.33 mm	NEW
Clough Capital Partners L P	1.14 mm	+1.14 mm	NEW
FMR	966.23 k	+966.23 k	NEW
Vanguard	556.42 k	+556.42 k	NEW
Bridgeway Capital Management	106.50 k	+106.50 k	NEW
Ensign Peak Advisors	0.00	-93.33 k	EXIT
RBF Capital	68.03 k	+68.03 k	NEW
FHI Federated Hermes	30.64 k	+30.64 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Press releases

From Benzinga Pro

Axonis Therapeutics Announces $115 Million Series A Financing

30 Oct 24

-- Oversubscribed financing brings together leading syndicate of life sciences investors -- -- Proceeds to support clinical development of first-in-class therapies for neurological disorders – BOSTON, Oct. 30, 2024